Skip to main content
[Preprint]. 2023 Sep 11:rs.3.rs-2248327. Originally published 2022 Dec 2. [Version 2] doi: 10.21203/rs.3.rs-2248327/v2

Figure 5. Infectivity of Ace2-expressing cells by the SARS-CoV-2 PVs and neutralization by neutralizing antibodies.

Figure 5.

(A) Fluorescent lentivirus pseudotyped with the SARS-CoV-2 S protein containing the different RBD potential variants (PV) were used to transduce ACE2-expressing HEK293 cells. In this setup, cell entry is dependent on ACE2 expression and cell fluorescence can be measured as a read-out for lentivirus transduction. (B) Equal amounts of lentivirus expressing the different PVs were used to transduce ACE2-expressing (ACE2+) and wild-type (ACE2−) HEK293 cells. Cell fluorescence was measured by flow cytometry and normalized by the % of cells transduced by lentivirus pseudotyped with the L strain. Data from 3 biological replicates is shown. (C) To assess the neutralization capacity of the indicated therapeutic antibodies, IC50s were first determined for neutralization of the L strain. (D) Ten-fold excess of the estimated IC50 concentrations of each antibody were pre-incubated with the different pseudotyped lentivirus variants before adding them to ACE2+ cells. Fluorescence values are normalized by the no IgG control. P-values < 0.05 as compared to the L strain RBD lentiviral particles are shown: n.s.: no significant. *, **, ***, ****: p values < 0.05, 0.005, 0.0005, 0.00005, respectively.